Recent Updates
Recently added Catalysts
SDGR Positive Sentiment

Schrödinger Reports Third Quarter 2026 Financial Results

Wednesday, November 4, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Schrödinger, Inc. reported strong financial results for Q3 2026, achieving a 17% growth in annual contract value (ACV) and generating $24 million in drug discovery revenue. The company also raised its full-year outlook for both ACV and drug discovery revenue, showcasing the effectiveness of its platform and business model.

Market Sentiment Analysis

POSITIVE FACTORS

  • 17% ACV growth reported.
  • $24 million in drug discovery revenue.
  • Raised full-year ACV and revenue outlook.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+15%
120-day peak, hindsight
Typical move
0.5%
average across 2 past catalysts
Cash runway
~33 mo
Minimal dilution risk
Lead asset
SGR-1505
Phase 1 · Mature B-Cell Neoplasm

Full Press Release Details

NEW YORK--(BUSINESS WIRE)---- $SDGR #AI--Schrödinger, Inc. (Nasdaq: SDGR) today announced financial results for the quarter ended September 30, 2026. “We are very pleased with our third quarter performance, delivering 17% ACV growth, $24 million of drug discovery revenue, and raising our full-year ACV and drug discovery revenue outlook. Our strong performance highlights the power of our industry-leading platform and also our business model in which our software and drug discovery businesses reinforce each ot

Frequently Asked Questions

What was Schrödinger's ACV growth in Q3 2026?

Schrödinger reported a 17% ACV growth for Q3 2026.

How much revenue did Schrödinger generate from drug discovery?

The company generated $24 million in drug discovery revenue.

Did Schrödinger raise its revenue outlook?

Yes, Schrödinger raised its full-year ACV and drug discovery revenue outlook.

What does ACV stand for?

ACV stands for Annual Contract Value.

ShareAdd on Google
Tags: SDGR Schrödinger Q3 2026 financial results drug discovery
Last updated: Nov 4, 2026

Biotech snapshot

Cash runway
$414M liquidity · $11M/mo burn
~33 mo
Minimal dilution risk
Lead asset
SGR-1505Phase 1
Mature B-Cell Neoplasm →

Catalyst track record

+15%
best trade around SDGR's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for SDGR.

See every catalyst's timing & PoA →